查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949523

核心臨床分子診斷市場－全球產業規模、佔有率、趨勢、機會及預測（依產品類型、技術、應用、最終用戶、地區及競爭格局分類，2021-2031年）

Core Clinical Molecular Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Technology, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球核心臨床分子診斷市場預計將從 2025 年的 66.5 億美元成長到 2031 年的 117.5 億美元，複合年成長率為 9.95%。

此領域涵蓋用於分析遺傳物質（例如DNA和RNA）的檢測系統和分析方法，旨在檢測對疾病診斷、風險評估和治療監測至關重要的生物標記。推動該領域成長的主要因素是慢性病和感染疾病）的日益流行，這使得高精度的檢測方法對於有效管理患者照護至關重要。此外，全球人口老化以及向預防性醫療保健模式的策略轉變，而非暫時的技術趨勢，才是推動對這些診斷工具需求的重要因素。

市場概覽
預測期 2027-2031
市場規模：2025年 66.5億美元
市場規模：2031年 117.5億美元
複合年成長率：2026-2031年 9.95%
成長最快的細分市場 核酸定序
最大的市場 北美洲

然而，由於複雜且高成本的檢測核准和合規法規結構，市場面臨許多障礙。嚴格的臨床證據和上市後監控標準常常導致產品上市延遲，並對企業資源造成巨大壓力。根據歐洲醫療技術協會（MedTech Europe）預測，到2024年，這些日益嚴格的監管將使體外診斷試劑生產商的維護和再認證相關成本增加70%。這種財務壓力對分子診斷解決方案的持續成長和普及構成了重大挑戰。

市場促進因素

PCR和次世代定序（NGS）平台的技術進步正透過提高檢測靈敏度和降低定序成本，從根本上改變全球核心臨床分子診斷市場。次世代定序的引入實現了多個基因的同時分析，這對於複雜診斷和精準醫療應用至關重要。高通量系統的快速工業化應用凸顯了這個轉變。根據Illumina公司於2024年2月發布的“2023會計年度第四季度及全年財務業績報告”，該公司在該會計年度共交付了352台旗艦產品NovaSeq X測序儀。這些先進的平台使臨床檢查室能夠更有效率地處理大量基因組數據，直接滿足了常規分子檢測流程中對速度的迫切需求。

同時，癌症和遺傳性疾病發生率的上升是市場擴張的主要驅動力，因此亟需強而有力的早期檢測解決方案。隨著全球癌症負擔的加重，醫療服務提供者越來越依賴分子譜分析來識別生物標記物，從而指導標靶治療方案的發展。世界衛生組織（WHO）於2024年2月發布的《全球癌症負擔》報告預測，2022年全球新增癌症病例將達到約2,000萬例。為了滿足日益成長的臨床需求，儘管面臨監管方面的挑戰，製造商仍在加速推動創新研發。 MedTech Dive網站2024年1月發表的一篇報導《FDA在2023年核准了創紀錄數量的新醫療設備》報道稱，美國FDA在2023年核准了124種新的醫療設備，證實了診斷領域強勁的研發勢頭。

市場挑戰

核心臨床分子診斷市場正受到日益複雜且高成本的法規環境的嚴重限制。隨著監管機構對臨床證據和上市後監測的要求日益嚴格，診斷設備開發商的財務和營運負擔也隨之加重。這種日益嚴格的監管迫使企業將大量資金和人力資源從研發活動中轉移出來，只是為了滿足監管要求。因此，新診斷測試的開發週期不斷延長，高昂的核准成本阻礙了專業測試的商業化，有效地抑制了創新並限制了產品系列的擴展。

這種不利局面直接阻礙了市場成長，降低了新技術在關鍵地區的吸引力。製造商越來越不願意優先考慮核准時間難以預測的市場，導致新產品上市數量減少。根據歐洲醫療技術協會（MedTech Europe）發布的《2024年報告》，選擇歐盟作為主要上市地區的領先體外診斷試劑製造商數量較先前的監管規定下降了40%。產品供應減少和最新診斷技術取得延遲正在損害市場潛力，迫使企業為了降低合規風險而放棄擴大策略。

市場趨勢

分散式即時就地檢驗的興起正在迅速重塑市場格局，將診斷能力從集中式基礎設施轉移到更貼近患者的場所。醫療系統正優先考慮這一趨勢，以縮短關鍵感染疾病管理中檢測結果的等待時間，使醫生能夠即時做出治療決策，而無需承受將檢體運送到中心檢查室帶來的物流延誤。這些快速檢測平台的日益普及也反映在近期的財務揭露中。在丹納赫公司於2024年1月發布的「2023年第四季及全年財務業績」中，其Cefeed業務部門報告稱，該季度呼吸道檢測以金額為準約為6.5億美元，遠超公司最初內部預測的3.5億美元。

同時，液態生物檢體在非侵入性腫瘤學領域的應用日益廣泛，透過簡單的抽血即可進行基因組分析，而非傳統的侵入性組織切片檢查，從而為癌症管理樹立了新的範式。這種調查方法克服了重複手術取樣帶來的臨床風險和時間安排上的挑戰，並有助於對患者進行長期監測和微量殘存疾病的檢測。隨著醫療機構將這些解決方案納入日常診療流程，市場接受度正穩步提升。根據Guardant Health於2024年2月發布的“2023會計年度第四季度及全年財務業績報告”，該公司臨床檢測量上年度39%，表明醫療機構對非侵入性診斷工具的偏好發生了顯著轉變。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球核心臨床分子診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（儀器、試劑和試劑盒、軟體和服務）
    • 透過技術（PCR、核酸定序、螢光原位雜合反應（FISH）、其他）
    • 依應用領域（感染疾病、遺傳性疾病、癌症篩檢等）
    • 按最終用戶分類（醫院和診斷檢查室、學術和研究機構、製藥和生物技術公司、受託研究機構(CRO) 等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美核心臨床分子診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲核心臨床分子診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區核心臨床分子診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲核心臨床分子診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲核心臨床分子診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球核心臨床分子診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • QIAGEN NV
  • Hologic Inc.
  • bioMerieux SA
  • Siemens Healthineers AG
  • Becton, Dickinson and Company
  • Agilent Technologies, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27524

The Global Core Clinical Molecular Diagnostics Market is projected to expand from USD 6.65 Billion in 2025 to USD 11.75 Billion by 2031, reflecting a CAGR of 9.95%. This sector comprises laboratory systems and assays that analyze genetic material, such as DNA and RNA, to detect biological markers essential for disease diagnosis, risk assessment, and therapeutic monitoring. Growth is largely driven by the rising prevalence of chronic conditions and infectious diseases, particularly cancer, which creates a critical need for high-precision testing methods to manage patient care effectively. Additionally, the aging global population and a strategic shift toward preventive healthcare models are significantly boosting demand for these diagnostic tools, distinct from temporary technological trends.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.65 Billion
Market Size 2031USD 11.75 Billion
CAGR 2026-20319.95%
Fastest Growing SegmentNucleic Acid Sequencing
Largest MarketNorth America

However, the market faces significant hurdles due to a complex and expensive regulatory framework regarding test approval and compliance. Rigorous standards for clinical evidence and post-market surveillance frequently delay product introductions and place a heavy strain on corporate resources. According to MedTech Europe, it was reported in 2024 that in vitro diagnostic manufacturers are experiencing a 70% increase in costs associated with maintenance and re-certification because of these intensified regulatory mandates. This financial pressure presents a substantial challenge to the sustained growth and accessibility of molecular diagnostic solutions.

Market Driver

Technological advancements in PCR and NGS platforms are fundamentally transforming the Global Core Clinical Molecular Diagnostics Market by improving test sensitivity and reducing sequencing costs. The implementation of next-generation sequencing enables the simultaneous analysis of multiple genes, which is vital for complex diagnostics and the application of precision medicine. This shift is highlighted by the rapid industrial adoption of high-throughput systems; according to Illumina's 'Financial Results for Fourth Quarter and Fiscal Year 2023' in February 2024, the company shipped 352 of its flagship NovaSeq X instruments during the fiscal year. These advanced platforms allow clinical laboratories to process massive volumes of genomic data more efficiently, directly meeting the critical need for speed in routine molecular testing workflows.

Concurrently, the rising incidence of cancer and genetic disorders serves as a primary catalyst for market expansion, necessitating robust solutions for early detection. As the global oncology burden increases, healthcare providers increasingly rely on molecular profiling to identify biomarkers that guide targeted treatment plans. According to the World Health Organization's 'Global Cancer Burden' release in February 2024, there were an estimated 20 million new cancer cases globally in 2022. To address this surging clinical demand, manufacturers are accelerating their innovation pipelines despite regulatory challenges; MedTech Dive's January 2024 article, 'FDA authorizes record number of new devices in 2023,' noted that the US FDA authorized 124 novel medical devices in 2023, underscoring the vibrant development activity within the diagnostic sector.

Market Challenge

The core clinical molecular diagnostics market is significantly constrained by an increasingly intricate and expensive regulatory environment. As authorities implement stricter mandates for clinical evidence and post-market surveillance, the financial and operational burdens on diagnostic developers have intensified. This regulatory rigor compels companies to divert substantial capital and personnel away from research and development activities solely to navigate compliance pathways. Consequently, development timelines for novel diagnostic assays are extended, and the high cost of approval discourages the commercialization of specialized tests, effectively stifling innovation and limiting portfolio expansion.

This burdensome landscape directly hampers market growth by making major regions less attractive for introducing new technologies. Manufacturers are increasingly hesitant to prioritize markets with unpredictable approval timelines, resulting in fewer new product launches. According to MedTech Europe in 2024, the number of large in vitro diagnostic manufacturers choosing the European Union as their primary launch geography dropped by 40% compared to previous regulatory directives. This contraction in product availability and delayed access to modern diagnostics undermines the market's potential as companies retreat from expansion strategies to mitigate compliance risks.

Market Trends

The shift toward Decentralized Point-of-Care Testing is actively restructuring the market by relocating diagnostic capabilities from centralized infrastructure to near-patient environments. This trend is prioritized by healthcare systems aiming to reduce turnaround times for critical infectious disease management, allowing physicians to make immediate therapeutic decisions without the logistical delays associated with core laboratory transport. The intensified utilization of these rapid platforms is reflected in recent financial disclosures; according to Danaher's 'Fourth Quarter and Full Year 2023 Results' in January 2024, the Cepheid business unit reported approximately $650 million in respiratory testing revenue for the quarter, a figure that significantly exceeded the company's original internal projection of $350 million.

Simultaneously, the expansion of Liquid Biopsy for Non-Invasive Oncology is establishing a new paradigm in cancer management by enabling genomic profiling through simple blood draws rather than invasive tissue biopsies. This methodology facilitates longitudinal patient monitoring and the detection of minimal residual disease, overcoming the clinical risks and scheduling difficulties associated with repeated surgical sampling. Market uptake of these solutions has been robust as providers integrate them into routine care; according to Guardant Health's 'Fourth Quarter and Full Year 2023 Financial Results' in February 2024, the company reported a 39% increase in clinical testing volume for the fiscal year, signaling a strong shift in provider preference toward these non-invasive diagnostic tools.

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Hologic Inc.
  • bioMerieux SA
  • Siemens Healthineers AG
  • Becton, Dickinson and Company
  • Agilent Technologies, Inc.

Report Scope

In this report, the Global Core Clinical Molecular Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Core Clinical Molecular Diagnostics Market, By Product Type

  • Instruments
  • Reagents & Kits
  • Software & Services

Core Clinical Molecular Diagnostics Market, By Technology

  • PCR
  • Nucleic Acid Sequencing
  • Fluorescence In Situ Hybridization (FISH)
  • Others

Core Clinical Molecular Diagnostics Market, By Application

  • Infectious Disease
  • Genetic Disorder
  • Cancer Screening
  • Others

Core Clinical Molecular Diagnostics Market, By End User

  • Hospitals & Diagnostic Laboratories
  • Academic & Research Institutions
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Others

Core Clinical Molecular Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Core Clinical Molecular Diagnostics Market.

Available Customizations:

Global Core Clinical Molecular Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Core Clinical Molecular Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Instruments, Reagents & Kits, Software & Services)
    • 5.2.2. By Technology (PCR, Nucleic Acid Sequencing, Fluorescence In Situ Hybridization (FISH), Others)
    • 5.2.3. By Application (Infectious Disease, Genetic Disorder, Cancer Screening, Others)
    • 5.2.4. By End User (Hospitals & Diagnostic Laboratories, Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Core Clinical Molecular Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Core Clinical Molecular Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Core Clinical Molecular Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Core Clinical Molecular Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Core Clinical Molecular Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Core Clinical Molecular Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. France Core Clinical Molecular Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Core Clinical Molecular Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Core Clinical Molecular Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Core Clinical Molecular Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia Pacific Core Clinical Molecular Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Core Clinical Molecular Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Core Clinical Molecular Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Core Clinical Molecular Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Core Clinical Molecular Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Core Clinical Molecular Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Middle East & Africa Core Clinical Molecular Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Core Clinical Molecular Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Core Clinical Molecular Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Core Clinical Molecular Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. South America Core Clinical Molecular Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Core Clinical Molecular Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Core Clinical Molecular Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Core Clinical Molecular Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Core Clinical Molecular Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Danaher Corporation
  • 15.3. Abbott Laboratories
  • 15.4. Thermo Fisher Scientific Inc.
  • 15.5. QIAGEN N.V.
  • 15.6. Hologic Inc.
  • 15.7. bioMerieux SA
  • 15.8. Siemens Healthineers AG
  • 15.9. Becton, Dickinson and Company
  • 15.10. Agilent Technologies, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer